BIOHOPE Scientific SL, the leading developer of Biotechnology diagnostic solutions to handle immunology of organ transplantation, is delighted to announce that it is to receive a grant of €3.8M in the latest round of Horizon 2020 SME Instrument Phase 2. The company will also benefit from 12 days of business coaching offered by the EC.
The company applied for the grant under the commission’s Open Disruptive Innovation Scheme which aims to foster the development of fast-growing, innovative SMEs with promising ideas bearing high disruptive potential in terms of products, services, models, and markets.
Biohope products cover two unmet clinical needs: a) 50% of transplanted kidneys are lost during the first 10 years because of chronic rejection, in spite of using immunosuppresor treatment for the entire life; b) 1/3 of transplanted patients die because of complications derived of the induced immunosuppression to prevent rejection.
BIOHOPE is currently developing two diagnostic solutions to handle the complex immunology management needed to avoid rejection in organ transplantation:
- DIAGNOSTIC SOFTWARE for: the early identification of patients at risk of chronic rejection or developing tolerance, enabling the clinicians to make early decisions on therapy adjustment
- COMPANION DIAGNOSTICS bioassay to support clinicians in the determination of the optimal combination/posology of immunosuppressant drugs
In the coming years, this highly valued EU funding support will enable to face the technological and clinical challenges of potential diagnostic tools and personalized therapy development in the field of renal transplantation.
Isabel Portero (CEO) said: “We are enormously proud to have been selected as one of the very few companies in the European Union to receive this funding. This grant allows us to face the clinical development of our products with the support of the European Commission. In addition, the project has been enriched with a consortium of some of the top specialist in the EU, and will also allow us to really improve our partnering & funding opportunities. Now we have the fuel to complete our R+D period and offer transplanted patients, doctors and Administrations, useful tools to improve current standards, which ultimately will save lives and sanitary expenses.”